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OBJECTIVES: Behcet’s disease is a form of systematic vasculitis that affects vessels of various sizes. Aortic
pseudoaneurysm is one of the most important causes of death among patients with Behcet’s disease due to its
high risk of rupture and associated mortality. Our study aimed to investigate the outcomes of Behcet’s disease
patients with aortic pseudoaneurysms undergoing open surgery and endovascular aortic repair.
METHODS: From January 2003 to September 2014, ten consecutive patients undergoing surgery for aortic
pseudoaneurysm met the diagnostic criteria for Behcet’s disease. Endovascular repair was the preferred
modality and open surgery was performed as an alternative. Systemic immunosuppressive medication was
administered after Behcet’s disease was definitively diagnosed.
RESULTS: Eight patients initially underwent endovascular repair and two patients initially underwent open
surgery. The overall success rate was 90% and the only failed case involved the use of the chimney technique to
reach a suprarenal location. The median follow-up duration was 23 months. There were 7 recurrences in
5 patients. The median interval between operation and recurrence was 13 months. No significant risk factors for
recurrence were identified, but a difference in recurrence between treatment and non-treatment with
preoperative immunosuppressive medication preoperatively was notable. Four aneurysm-related deaths
occurred within the follow-up period. The overall 1-year, 3-year and 5-year survival rates were 80%, 64%
and 48%, respectively.
CONCLUSIONS: Both open surgery and endovascular repair are safe and effective for treating aortic
pseudoaneurysm in Behcet’s disease patients. The results from our retrospective study indicated that
immunosuppressive medication was essential to defer the occurrence and development of recurrent aneurysms.
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’ INTRODUCTION
Behcet’s disease (BD) is particularly common in regions along
the Silk Road from the Mediterranean to the Far East. This
disease manifests as oral and genital ulcerations, skin lesions,
uveitis and vascular, central nervous system and gastrointestinal
involvement (1). As BD is a systemic vasculitis of small and large
vessels, including both veins and arteries, large vascular damage
in BD patients, termed vasculo-BD, is characterized by venous
thrombosis, arterial occlusion and aneurysm. Vasculo-BD has
been reported to occur in 14.7% - 27.7% of BD patients
(2,3). Arterial involvement has drawn special attention due to
its significant association with mortality, as this compli-
cation accounts for over a quarter of all BD-related deaths (4).
Although pulmonary arterial aneurysm is much more common
in BD patients than in the general population, aortic aneurysm
remains one of the principal causes of death due its high risk of
rupture and associated mortality (5).
Surgical repair combined with systemic immunosuppres-
sant administration has been recommended for peripheral
arterial aneurysm and this recommendation is primarily
supported by experience and evidence from open trials and
observational studies (6). Surgical bypass was formerly the
traditional choice, and its safety and effectiveness for
enabling survival of aneurysmal rupture have been con-
firmed. However, anastomotic pseudoaneurysm is a majorDOI: 10.6061/clinics/2016(06)03
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adverse event. Hosaka reported that the overall 5-year
cumulative incidence of anastomotic pseudoaneurysm for-
mation after open surgery was 12.9% (7).
Endovascular aortic repair (EVAR) is minimally invasive,
is completed in a short operative time and does not require
general anesthesia. This method has been demonstrated to be
an ideal urgent operative modality for patients with a
ruptured abdominal aortic aneurysm (AAA) (8,9). Moreover,
the introduction of EVAR should reduce the recurrence of
pseudoaneurysms at arterial anastomoses in BD patients
(10). Several studies have focused on the efficacy and safety
of endovascular treatment for vasculo-BD patients, but
clinical evidence indicating the prognosis of BD patients
with aortic pseudoaneurysms after EVAR remains lacking.
The purpose of this study was to investigate the outcome
of a series of BD patients undergoing EVAR for aortic
pseudoaneurysms.
’ MATERIALS AND METHODS
Clinical database and diagnostic criteria
With the approval of the institutional ethics committee, we
conducted this retrospective study of the aortic aneurysm
database at the Department of Vascular Surgery, Peking
University People’s Hospital. We searched our center’s records
of patients with aortic aneurysm undergoing surgery between
January 2003 and September 2014 and we screened the enrolled
cohort. Aortic pseudoaneurysm was confirmed by computed
tomography angiography (CTA) and/or aortic angiography.
The diagnosis of BD was confirmed according to the criteria
described by the International Study Group for Behcet’s
Disease. These criteria require the presence of recurrent oral
ulceration in association with at least two of the following:
characteristic ocular lesions, characteristic skin lesions, genital
ulceration and a positive pathergy test result (12). Accordingly,
10 patients with BD undergoing open surgery or EVAR for
aortic pseudoaneurysm constituted the final cohort.
The data were independently abstracted from medical
records by two authors and were reviewed by the
corresponding authors. The variables of interest included
demographic characteristics, medical history and medica-
tions, laboratory test results, surgical records, postoperative
medications and adverse events. Preoperative CTA was
performed on all patients, not only to produce exact
diagnostic evidence but also to provide an important
reference for the individualized selection of an operative
modality. Pseudoaneurysms whose outlets were located 2 cm
below the outlets of the renal arteries were termed infra-
renal, while those with outlets less than 2 cm below the
outlets of the renal arteries were termed pararenal. Indica-
tions for endovascular or surgical intervention were acute
symptoms including onset of worsening abdominal or back
pain, organic dysfunction causing visceral hypoperfusion,
unstable blood pressure or shock and any other evidence
indicating aneurysmal rupture. Urgent indications such as
acute onset of back and/or abdominal pain and abdominal
tenderness on palpation with no signs of pseudoaneurysmal
rupture on CT scans were established for surgical interven-
tion within 24 hours (11).
Technical surgical description
EVAR was the preferred modality for aortic pseudoaneur-
ysm. Puncture for percutaneous access was performed
through the right or bilateral common femoral artery under
local anesthesia. The final decision concerning stent type and
size was made by a surgeon according to the results of aortic
angiography. This decision was also restricted based on the
availability of a stent graft of the appropriate size at the time
of the procedure. The extent of oversizing was typically 10%
to 20% larger than the diameter of the aneurysmal neck
diameter and was restricted to a maximum of 30% in urgent
cases. Given the possibility of aortitis lesions near the
pseudoaneurysm in vasculo-BD patients, for infra-renal
aortic pseudoaneurysms, we placed the stent graft proxi-
mally exactly at the level of the inferior renal artery.
A tubular stent graft was used for aneurysmal lesions
located at the middle segment of the infra-renal abdominal
aorta, whereas an aorto-uni-iliac or bifurcated stent graft was
selected for aortic lesions near the aortic bifurcation while
conducting an evaluation of the blood supply of the involved
lower extremity. The stent grafts selected consisted of Zenith
(Cook Medical, Bloomington, IN, USA), Endurant (Medtro-
nic, Santa Rosa, CA, USA), Excluder (W.L. Gore &
Associates, Flagstaff, AZ, USA) and Hercules-T (MicroPort
Medical, Shanghai, China). The chimney technique and the
multiple stent technique were adopted based on the
individualized anatomy and the availability of stents for
patients with juxtarenal or suprarenal pseudoaneurysms.
Technical success was defined as the complete isolation of
the aortic pseudoaneurysm without any type of endoleakage
as confirmed by angiography.
As an alternative to EVAR, open surgery was performed
under exceptional circumstances. General anesthesia was
provided and all patients were managed in the intensive care
unit post-operatively for one day. Prosthesis grafts with
diameters similar to visually normal aortas were used.
Interposition with end-to-end anastomosis was performed
in the aorta and visceral reconstruction was conducted via
end-to-end or end-to-side anastomosis. Aspirin at a dose of
100 mg per day was administered to patients undergoing
aortic replacement, and dual antiplatelet therapy was
administered to those undergoing visceral reconstruction.
Technical success was defined as pseudoaneurysm removal
and patency of visceral artery reconstruction.
Medication strategy
Systemic immunosuppressive medication was administered
under the suggestion of a rheumatic physician once BD was
diagnosed. The erythrocyte sedimentation rate (ESR) and the
C-reactive protein (CRP) level were used to estimate the status
of rheumatic activity as a reference for medication adjustment.
The normal ranges of ESR and CRP levels in our core
laboratory were 0–15 mm/h (for males) and 0–8.00 mg/L,
respectively.
Follow-up evaluation
Follow-up was performed in March 2015. First, we
contacted all enrolled patients by telephone and confirmed
their survival status. Second, we recorded the date and cause
of death for the non-surviving patients and we asked the
surviving patients to visit for further consultation. Aortic
ultrasound was used to identify aortic recurrence; aortic CTA
was used as an alternative for those without contraindica-
tions, such as renal insufficiency. ESR and CRP levels were
tested to evaluate rheumatic activity. Additionally, data
regarding medication prescriptions by outpatient services,
especially immunosuppressive, antiplatelet, anticoagulation
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Table 1 - Demographic characteristics and follow-up data.
No. Sex &
Age
Symptoms and
time of BD
diagnosis
ESR prior to
operation
(mm/h)
CRP level prior to
operation (mg/L)
Involved vessels
beyond the aorta
Chief complaint Duration from
admittance to
operation
Surgical treatment Systemic
immunosuppressive
treatment
Duration of
follow-up
1 M, 45 O, G, E
Diagnosed after
the second
recurrence
61 75 - Continuous back
pain for 2 months
and sudden
exacerbation to
unconsciousness
within 2 hours
30 minutes Aneurysmectomy
reconstructed by
aortic and bi-iliac
artery interposition
Recurrence at the
proximal aortic
anastomosis;
underwent another
aortic interposition
10 months after the
first operation
Recurrence again at
the proximal aortic
anastomosis and
too close to renal
artery to perform
EVAR 8 months
after the second
operation
After rejection of
surgery for the
second recurrent
pseudoaneurysm,
prednisone qd 80
mg for 1 month
followed by 50 mg
for 6 months and
25 mg for 6 months,
as well as
cyclophosphamide
q2w 400 mg for
3 months followed
by q4w 400 mg for
3 months
30 months, dead
(rupture of
recurrent
pseudoaneurysm
at proximal aortic
anastomosis)
2 M, 29 O, G, E
1 day
Diagnosed prior
to the initial
open surgery
105 421 Right renal artery
pseudoaneurysm
Sudden tearing
abdominal pain
15 days prior,
followed by
continuous dull
pain
4 days Prosthesis bypass
from the aorta to
the SMA, bilateral
renal arteries, and
bilateral CIA with
aneurysmectomy
Pre-operative
prednisone 40 mg
once
Post-operative
prednisone qd
40 mg for 12
months followed by
sequential
reduction to drug
withdrawal
58 months, alive
(normal ESR and
CRP level)
3 M, 45 O, E, S
Diagnosed
more than 6
years prior to
the initial EVAR
- - - Continuous
abdominal pain
combined with
pulsatile
abdominal mass
for 1 month,
acute
enlargement of
the mass for 1 day
3 hours Infra-renal EVAR
Recurrence at the
proximal end of the
endograft
accompanied by
right femoral
anastomotic
pseudoaneurysm 6
months after the
initial EVAR, patient
refused further
intervention for
aortic recurrence
Pre-operative
prednisone for
more than 6 years
Post-operative
prednisone qd
30 mg and
azathioprine qd
100 mg for
7 months
7 months, dead
(rupture of
recurrent
pseudoaneurysm
at proximal aortic
landing zone)
4 M, 33 O, G, S
Diagnosed
more than 3
years prior to
the initial EVAR
10 62.8 Left subclavian
aneurysm, Left
renal arterial
occlusion
Continuous dull
epigastric pain for
1 month
6 days EVAR with right
renal artery and
SMA chimney
stenting
Technical failure
due to type I
endoleakage
Pre-operative
prednisone qd
40 mg,
Cyclophosphamide
q2w 400 mg for
36 months,
prednisone qd
60 mg 1 month
before operation
and continued
post-operatively
4 months, dead
(rupture of
aneurysm due to
type Ia endoleak)
5 M, 28 O, G, S
Diagnosed
approximately 1
year prior to
the first
recurrence
26 19.6 Right renal artery
stenosis
Continuous
abdominal and
back pain for 3
months
6 days Infra-renal EVAR
(Zenith, 22 mm/80
mm)
Recurrent
pseudoaneurysm at
the distal end of the
endograft, followed
by another infra-
renal EVAR (Aorto-
bi-iliac) 80 months
after the initial
EVAR
Recurrent
pseudoaneurysm at
the proximal end of
the endograft
above the right
renal artery 13
months after the
second EVAR; the
size was stable
based on close
follow-up
Prednisone qd
30 mg for 12
months before the
first recurrence,
continued qd 30 mg
post-operatively for
another 12 months,
qd 15 mg for half a
year and qd 10 mg
as a maintenance
treatment
163 months, alive
(regular
hemodialysis
owing to chronic
kidney failure for
65 months)
6 M, 56 O, G, S
Diagnosed after
the initial EVAR
72 176 Left CIA
pseudoaneurysm
Continuous pain
in back and lower
extremities for
2 months
2 days Infra-renal EVAR
(Medtronic,
25-14 mm /100 mm)
combining artificial
bypass from the
right CFA to the left
Prednisone qd
50 mg for
6 months followed
by sequential
reduction by 5 mg
50 months, dead
(sudden death,
rupture of
recurrent
aneurysm)
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medications, were reviewed in our center’s database for all
enrolled patients.
Statistical analysis
Quantitative variables were described as medians and
extreme ranges and qualitative variables were expressed as
numbers and percentages. Data were pooled and analyzed
using SPSS version 19.0 (IBM SPSS, Chicago, IL). The patients
were removed from the study upon death or loss to follow-up.
’ RESULTS
Patient characteristics
The final enrolled cohort was composed of 10 patients, all
of whom were male. The median age was 41 years (from
29 years to 56 years). The most common chief complaint was
durative abdominal or back dull pain, although 2 patients
(20%) presented with abdominal masses. Six patients (60%)
had extravascular damage, including 5 arterial aneurysm/
pseudoaneurysm lesions, 3 arterial stenosis/occlusion
lesions and 1 deep venous thrombosis. The renal artery
was the most frequently involved artery (3 out of 10 patients,
30%) and other involved arteries included the superior
mesenteric artery (SMA), common iliac artery (CIA),
subclavian artery and coronary artery (Table 1).
Three patients had been diagnosed with BD prior to the
manifestation of aneurysm-related symptoms under pre-
operative systemic immunosuppressive medication. One
patient was appropriately diagnosed with BD soon after
admittance and thus received a high dose of prednisone
before open surgery. The remaining 6 patients received
systemic immunosuppressive medication after open surgery
or EVAR once the diagnosis was confirmed. An elevated ESR
was observed in 8 out of 9 patients, and an elevated CRP
level was detected in all 9 patients. The median ESR and CRP
level were 61 mm/h (from 10 mm/h to 105 mm/h) and
CFA and plugging
of the left CIA
Rupture of
recurrent aneurysm
50 months after the
initial operation
every two weeks
after EVAR
7 M, 39 O, G, E
Diagnosed after
the initial EVAR
45 24.2 - Back pain for half
a year and
pulsatile
abdominal mass
for 20 days
5 days Infra-renal EVAR
(Hercules,
20-20 mm/60 mm)
Recurrent
pseudoaneurysm at
the distal end of the
endograft, followed
by another infra-
renal EVAR
(Aorto-bi-iliac)
73 months after the
initial EVAR
Prednisone and
azathioprine for
approximately
3 years after the first
EVAR, leflunomide
qd 20 mg for
12 months after the
second EVAR
108 months, alive
(normal ESR of
8 mm/h and CRP
level of
6.29 mg/L)
8 M, 35 O, G, P
Diagnosed after
the initial EVAR
30 66.8 Right CIA
occlusion, SMA
aneurysm
Intermittent
epigastric pain for
more than 1 year
2 days Juxta-renal EVAR
(Sinus XL.
22 mm/80 mm,
24 mm/80 mm)
combining coil
embolization and
PTA stenting for the
R-CIA
Prednisone qd
50 mg for
6 months followed
by sequential
reduction by 5 mg
every two weeks,
Cyclophosphamide
q2w 400 mg for
16 months after the
initial intervention
16 months, alive
(normal ESR of
3 mm/h and
slightly elevated
CRP level of
11.20 mg/L, new
aneurysm at the
proximal landing
zone of the bare-
metal iliac stent)
9 M, 42 O, G, S
Diagnosed 3
years prior to
the initial EVAR
98 285 Coronary artery
circumflex
aneurysm, deep
venous
thrombosis
Intermittent
thoracic pain for
more than 2 years
and abdominal
pain for 3 months
1 day TEVAR (Hercules,
26 mm/80 mm) and
infra-renal EVAR
(Hercules,
18 mm/80 mm)
Pre-operative
prednisone qd
50 mg for
10 months followed
by 25 mg for
12 months, 15 mg
for 3 months and
7.5 mg for
11 months, as well
as Cyclophosphamide
q2w 400 mg for
24 months
Post-operative
adalimumab q2w
40 mg combined
with prednisone qd
5 mg for 12 months
followed by
prednisone qd
20 mg and
azathioprine
150 mg for
4 months
16 months, alive
(normal ESR of
10 mm/h and CRP
level of
1.50 mg/L)
10 M, 46 O, G, E
Diagnosed after
the initial EVAR
74 88 - Abdominal and
back pain for over
10 days, acute
deterioration for
12 hours
1 hour Infra-renal EVAR
(Hercules,
18 mm/80 mm)
Post-operative
prednisone
30 mg qd for
3 months, and
increase to 50 mg
up to present,
azathioprine
100 mg bid up to
present
9 months, alive
(normal ESR of
13 mm/h and CRP
level of 3.32 mg/L)
Abbreviations: O: ocular lesions; S: skin lesions; G: genital ulceration; E: uveitis; P: positive pathergy test result.
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75 mg/L (from 19.6 mg/L to 421 mg/L), respectively.
Prednisone was the initial systemic immunosuppressive
medication for all patients and the initial dose was
approximately 1 mg/kg per day. Cyclophosphamide was
simultaneously administered to 5 patients and azathioprine
to another 4 patients. One patient was prescribed adalimu-
mab, a TNF-inhibiting anti-inflammatory drug.
In 7 patients, the outlet of the aortic pseudoaneurysm was
located more than 2 cm below the outlet of the renal artery;
in 2 patients, this outlet was located at the level of the renal
artery outlet; and 1 patient, this outlet was located at the
aorta between the SMA and renal artery (Figure 1).
Additionally, the patients with infra-renal pseudoaneurysm
had another pseudoaneurysm at the descending aorta and
another patient with suprarenal pseudoaneurysm had multi-
ple saccular aortic aneurysms at the descending aorta as well
as the supra-renal and infra-renal abdominal aorta.
Surgical outcome
Eight patients underwent initial EVAR. 2 patients under-
went initial open surgery: one patient exhibited shock due to
acute pseudoaneurysmal rupture upon arrival at the
emergency room and a stent graft was unavailable; the
other patient had a challenging anatomy with involve-
ment of the SMA and right renal artery. The overall
technical success rate was 90% (9/10). The failed case was
a pararenal aortic pseudoaneurysm accompanied by left
renal arterial occlusion; the right renal artery and SMA
were reconstructed via chimney graft deployment (self-
expansive bare-nitinol stent). Type I endoleakage was
identified on aortic angiography. The patient died due to
rupture of the pseudoaneurysm 4 months after the initial
EVAR. One patient requested additional thoracic EVAR
for an accompanying thoracic aortic pseudoaneurysm
(Figure 2) and another patient underwent percutaneous
transluminal balloon angioplasty and stenting (self-expan-
sive bare-nitinol stent) for combined right CIA occlusion
the day after the initial EVAR using multilayer stenting
and coiled embolization (Figure 3). Two urgent EVARs
were performed on patients who suffered from rapidly
worsening abdominal pain and technical success was
achieved in both cases. No deaths occurred within 30
days after surgery.
Table 2 - Summary of the published studies on open surgery and EVAR for aneurysmal lesions in patients with BD.
First
author
Published
year
Total
no.
of
cases
Involvement Number
of open
heart
surgeries
Number of
EVAR
procedures
Number of
aneurysm-related
deaths
Number of
recurrences
Systemic
immunosuppressive
medication
Follow-
up
(months)
Kwon 2008 12 Abdominal
aortic aneurysm
21 0 1 / 12
(rupture of
recurrent
aneurysm)
8//21
(38.1%)
Only postoperative
medication (steroids,
colchicine, azathioprine, or
cyclophosphamide)
was administered to all
patients
45.4
Tuzun 2012 25 Peripheral
arterial
aneurysm
22 0 1/22
(anastomotic
dehiscence)
5/22
(22.7%)
Immunosuppression with
cyclophosphamide
and corticosteroids before
intervention and continued
post-operatively
88.8
Yang 2013 21 Peripheral
arterial lesions
24 10 1/21
(leakage after
EVAR and
consequent
rupture of
pseudoaneurysm)
10/21
(47.6%)
Combination of medications
including azathioprine,
steroids and colchicine
before intervention except in
10 patients who had been
referred from other institutes
78.7
Park 2001 7 Peripheral
arterial
aneurysm
0 9 0 1/7 (14.3%) Not described. 28
Kwon 2003 9 Arterial
pseudoaneurysm
0 11 0 1/9 (11.1%) Immunosuppressive agents
(azathioprine,
prednisolone) before and
after the procedure except in
1 patient with a delayed
diagnosis
24.1
Kim
WH
2009 34 Non-cerebral
arterial
aneurysm
7 16 1/23
(aneurysm-
related death
after EVAR)
4/23
(17.4%)
Prednisolone 60 mg/d before
intervention to induce
remission
47.6
Liu 2009 10 Aortic
pseudoaneurysm
0 10 1/10
(rupture of
recurrent
pseudoaneurysm)
2/10 (20%) All patients received
immunosuppressive therapy
before and after intervention
21.5
Kim
SW
2014 10 Aortic
pseudoaneurysm
0 10 0 1/10 (10%) Immunosuppressive
therapy at the time of EVAR
and continued during
follow-up except in 1 patient
57
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Follow-up
The median follow-up duration was 23 months (from 4 to
163 months, IQR 11 – 56 months). There were 7 recurrences
in 5 patients (50%), consisting of 6 aortic recurrences and
1 femoral anastomotic recurrence. The median interval
between previous operation and recurrence manifestation
was 13 months (from 6 to 80 months, IQR 9–61.5 months).
Moreover, the patient who underwent iliac stent deployment
developed an iliac pseudoaneurysm proximally at the iliac
stent, but the aortic pseudoaneurysm had disappeared
16 months after multiple bare-metal stents were placed for
repair. The size of the new lesions was stable on the CTA
imaging series and thus, no further intervention was
performed.
Four aneurysm-related deaths occurred within the follow-
up period. The overall 1-year, 3-year and 5-year survival rates
were 80%, 64% and 48%, respectively. One of these patients
was found to have type I endoleakage after EVAR, which
required open surgery; however, because he exhibited multi-
ple aortic aneurysms, thoracoabdominal aortic replacement
was indicated. Finally, that patient refused further interven-
tion and although immunosuppressive medication was
administered, he died due to pseudoaneurysmal rupture.
Three patients suffered from rupture of recurrent aortic
pseudoaneurysms. Although one patient experienced sudden
rupture of an undiscovered recurrent pseudoaneurysm, the
other two patients requested careful follow-up instead of
further surgery when recurrence was identified.
Figure 1- (A) Pararenal pseudoaneurysm and (B, C) infrarenal pseudoaneurysm.
Figure 2- A 42-year-old male with descending thoracic and infrarenal abdominal aortic pseudoaneurysms (A, B). Aortogram- following
stent graft placement demonstrating that the aneurysm was successfully isolated (C, D). At the 1-week, 2-month, 6-month, and 12-
month follow-up exams (E, F, G, H), three-dimensional volume rendering computed tomography (CT) images revealed that the
aneurysm had completely regressed.
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’ DISCUSSION
In the present study, we retrospectively studied our
experience in the treatment of BD patients with aortic
pseudoaneurysms. Aortic pseudoaneurysm without surgical
treatment had a very high mortality rate (up to 61%) due to
pseudoaneurysmal rupture. Mulder et al. reported that the
mortality rate of patients with non-infected pseudoaneurysms
receiving nonsurgical treatment was up to 61% due to
documented rupture; thus, the repair of all aortic pseudoaneur-
ysms was strongly recommended (13). Considering that rupture
of aortic pseudoaneurysms accounted for most deaths of
these vasculo-BD patients, aggressive surgical interventions
are indicated for all BD patients with aortic pseudoaneurysms.
The outcomes of our cohort confirmed the safety of EVAR for
aortic pseudoaneurysm in BD patients, especially in emergency
cases. There were no immediate complications from the stent
graft procedures within 30 days after EVAR. Despite the
controversy concerning the survival advantage of EVAR over
open surgery for ruptured AAA (14), the excellent periopera-
tive benefits of EVAR were convincing, as demonstrated in
Veith’s study (8). Additionally, urgent open surgery was
associated with many difficulties related to blood preparation,
pre-anesthetic assessment and control of comorbidities, which
lead to a high risk of perioperative complications (11,15,16).
The widespread adoption of minimally invasive EVAR for
aortic pseudoaneurysms in BD patient has been consistent
with the trend in treatment for AAAs and its improv-
ement in perioperative mortality was confirmed in our study
(10,17-20).
However, complex AAA in BD patients, such as short
infra-renal neck, juxtarenal or suprarenal locations, was
not rare and the challenging anatomy of these patients
limited endovascular repair and was associated with high
morbidity and mortality. We observed that death related to
failure of EVAR, predominantly in cases of complex AAA,
was a predominant feature of postoperative short-term
death. Yang reported that the only death in his cohort
presented with leakage of a proximal anastomosis after
repair of a ruptured AAA after undergoing stent-graft
insertion. The patient ultimately died of ruptured pseudoa-
neurysm in the proximal and distal ends of the stent graft
during the follow-up period (21). Similarly, the only failed
procedure in our cohort occurred in a patient with a
pararenal pseudoaneurysm. A fenestrated or branched
endograft might be an alternative option for cases of
technical failure (22); however, no branched endograft
products were available in China and the fenestrated
endograft used by Cook required a wait time of at least
two weeks. For pseudoaneurysms with a complex anatomy
in BD patients, effective and efficient surgical modalities
remain under development and improvement.
We found that the frequency of post-operative recurrence
was relatively high in our cohort. Open surgery had
traditionally been the mainstream treatment for aortic
pseudoaneurysms in BD patients, but the high rate of
recurrence of this procedure troubled surgeons. Among the
studies in which open surgery was performed on the
majority of the study population, the rate of pseudoaneur-
ysm recurrence varied from 22.4% to 47.6% (21,23,24).
With the maturation of EVAR for AAA and the evidence
of its benefit based on extensive studies, the rate of
recurrence decreased to 10-20% in recent studies, in which
most patients underwent EVAR as the initial intervention
(Table 3)(10,20,25-27). In our cohort, EVAR was the primary
surgical modality, but the rate of recurrence in this study
was similar to that of previous studies performing open
surgery.
Figure 3- A 35-year-old male with suprarenal abdominal aortic pseudoaneurysm combined with right iliac arterial occlusion (A).
Double- bare-metal stent placement combined with coiled embolization to treat the aortic lesion (B), following by balloon angioplasty
and self-expansive bare-nitinol stent placement (C). At the 1-week follow-up, three-dimensional volume rendering CT showed obvious
attenuation (D), and the lesion was barely detectable at the 2-month, 9-month and 15-month follow-up examinations (E, F, G). As
indicated by the red arrow in the images below, a new aneurysm at the proximal end of the bare-metal stent of the iliac artery was
detected at the 2-month follow-up examination and its size was stable in the subsequent follow-up examinations under close
surveillance.
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Further analysis demonstrated that the absence of systemic
immunosuppressive medication prior to intervention in
several patients might account for the abnormally high rate
of recurrence in this study. The European League Against
Rheumatism (EULAR) recommended that peripheral artery
aneurysms require surgical repair accompanied by systemic
immunosuppressive mediation [6]. Considering the studies
reporting excellent outcome and a lack of recurrence, Liu and
Kim stated that all patients in their studies received
immunosuppressive medication to induce remission prior
to intervention and that this treatment continued after
intervention (20,27). Additionally, Kwon and Kim reported
that only 1 patient in their cohort did not receive
preoperative immunosuppressive medication due to a
delayed diagnosis after intervention and exhibited co-
morbid bilateral femoral head avascular necrosis, in which
prednisone was contraindicated (10,26). In contrast, 6 out of
10 patients (60%) in our cohort had not received preoperative
immunosuppressive medication, and 4 out of these 6 patients
(66.7%) experienced recurrence. These patients did not
receive systemic immunosuppressive treatment prior to
EVAR because their diagnosis of BD was made after EVAR.
Additionally, the preoperative ESR and CRP level in our
cohort were clearly higher than those reported by Liu.
Because ESR and CRP levels reflect the status of autoimmune
activity, this observation indicated that the patients in our
study were in an active stage of BD, which is strongly
suspected to be associated with the high rate of recurrence in
this study. Consequently, we believe that immunosuppres-
sive medication was essential to defer the occurrence and
development of recurrent aneurysms. However, further
studies are needed to clarify related issues, including the
necessary preoperative immunosuppressive treatment dura-
tion and regimen, the operative timing and the surveillance
protocol.
The lessons from our study call attention to the co-
morbidity of autoimmune disease with aortic pseudoaneur-
ysm. The most common cause of aortic pseudoaneurysm
was trauma, which was precisely diagnosed according to
the medical history. However, concerning aortic pseudoa-
neurysm of unknown etiology, autoimmune disease should
receive greater emphasis. The applied International Study
Group (ISG) clinical diagnostic criteria for BD established in
1990 featured five specific syndromes for the diagnosis of
BD: recurrent oral ulcerations, characteristic ocular lesions,
characteristic skin lesions, genital ulcerations and positive
pathergy test results (12). However, further studies showed
that in 7-30% of these patients, vascular involvement was
observed before the clinical diagnosis of BD (28,29). This
delay in diagnosis led to a lack of prompt immunosup-
pressive medication for aortic pseudoaneurysm prior to
intervention because of the urgency of surgical aortic repair
to resolve the life-threatening risk to the patients. Fortu-
nately the new International Criteria for BD (ICBD)
published in 2014 included vascular manifestations as a
class of clinical manifestations with diagnostic significance
(30). Compared to the ISG diagnostic criteria, the ICBD was
assumed to improve the prompt diagnosis of BD for
patients with arterial involvement. In our study, neither
the ESR or CRP level prior to operation nor the use of
azathioprine or cyclophosphamide appeared to have a
significant effect on recurrence. The proper duration and
regimens of systemic immunosuppressive medication were
not addressed in the EULAR recommendations (6). ESR and
CRP levels serve as biomarkers for evaluating the status of
BD activity. In our cohort, both azathioprine and cyclopho-
sphamide were used and no significant difference in
outcome between azathioprine and cyclophosphamide
was observed. The optimal medical strategy will depend
on additional evidence from multicenter large-scale con-
trolled trials and this issue was beyond the scope of this
study.
Our single-center study had a small sample size due to
the low prevalence of BD patients with aortic pseudoa-
neurysm, and this small sample size rendered further
univariate/multivariate analysis impossible. Additionally,
over the wide time span (from 2003 to 2014) of the study,
there was exciting and splendid progress in endovascular
techniques; therefore, estimating the effect of these
techniques among all patients may be somewhat unrea-
sonable. However, our study remains of significance
because of the current shortage of clinical experience in
aortic pseudoaneurysms in BD patients; thus, the out-
comes of our cohort together with the findings other
published results by Kwon, Kim WH, Liu and Kim SW
et al. could help to clarify the optimal surgical manage-
ment for these patients (10,20,26,27).
Both open surgery and endovascular repair are safe and
effective for treating aortic pseudoaneurysm in BD patients
and these modalities directly decrease the high risk of death
due to aortic pseudoaneurysmal rupture. However, effective
immunosuppressive medication may be another essential
factor in deferring the occurrence and development of
recurrent aneurysms, although this conclusion requires
additional evidence.
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